Spectrum Pharmaceuticals Inc (SPPI)
NASDAQ NASDAQ Primary Summary
SPPI Chart
Osivax Announces Last Patient Last Visit in Phase 2a Trial Evaluating a Booster Dose of Broad-Spectrum Influenza Vaccine OVX836 s release
Lyon, France – June 5, 2025 – Osivax, a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating respiratory viruses, today announced that all participants have completed their final visit in the Phase 2a clinical booster trial (NCT06582277) evaluating OVX836, Osivax' broad-spectrum influenza A vaccine candidate. Osivax expects to announce final results from the booster trial in H2 2025.
Bio-Thera Solutions Publishes Phase I Clinical Study Results for BAT4406F, an ADCC-Enhanced Fully Humanized Anti-CD20 Monoclonal Antibody, in Patients with Neuromyelitis Optica Spectrum Disorders
GUANGZHOU, China , Jan. 14, 2025 /PRNewswire/ -- Bio-Thera Solutions, Ltd. today announced the publication of the Phase I clinical study results for BAT4406F, an ADCC-enhanced fully humanized anti-CD20 monoclonal antibody in Chinese patients with neuromyelitis optica spectrum disorders (NMOSD) in the journal CNS Neuroscience & Therapeutics.
STALICLA publishes pioneering phase 1b data on precision treatment for autism spectrum disorder in Biomedicines
Press Release STALICLA's precision psychiatry study highlights strong EEG-based target engagement of STP1 treatment in defined subgroup of patients with autism and numerical improvement in core symptoms Geneva, Switzerland – June 27, 2024 – STALICLA SA, a Swiss neuro precision biotech company dedicated to developing precision medicine-based treatments for neuropsychiatric and neurodevelopmental disorders, today announced the publication of a landmark phase 1b study with STP1, a novel combination therapy tailored for the treatment of a clinically and biologically defined subgroup of patients with autism spectrum disorder (ASD), named ASD Phenotype 1 (ASD-Phen1). The results of the study were published in the peer-reviewed journal Biomedicines, in an article titled “Safety, Tolerability, and EEG-Based Target Engagement of STP1 (PDE3,4 Inhibitor and NKCC1 Antagonist) in a Randomized Clinical Trial in a Subgroup of Patients with ASD”.
Spectrum Pharmaceuticals Inc Dividends
| SPPI 18 Dec 2012 Paid | Other | $0.15 Per Share |
Spectrum Pharmaceuticals Inc Earnings
| SPPI 18 Dec 2012 Paid | Other | $0.15 Per Share |
Spectrum Pharmaceuticals Inc (SPPI) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Spectrum Pharmaceuticals Inc ever had a stock split?
Spectrum Pharmaceuticals Inc Profile
| Biotechnology Industry | Healthcare Sector | Mr. Thomas J. Riga CEO | NASDAQ Exchange | 84763A108 Cusip |
| US Country | 86 Employees | - Last Dividend | 6 Sep 2002 Last Split | - IPO Date |
Overview
Spectrum Pharmaceuticals, Inc. is a leading biopharmaceutical company dedicated to the development and commercialization of innovative therapies in oncology and hematology. The company, originally founded in 1987 as NeoTherapeutics, Inc., underwent a transformation in December 2002, adopting its current name to better reflect its focus on a broad range of spectrum in pharmacology, especially catering to cancer care. Based in Boston, Massachusetts, Spectrum Pharmaceuticals has established itself as a key player in addressing unmet medical needs through its cutting-edge research and strategic partnerships. Among its noteworthy collaborations are agreements with Hanmi Pharmaceutical Co. Ltd., The University of Texas M.D. Anderson Cancer Center, and ImmunGene, Inc., aimed at enhancing its research capabilities and expanding its product portfolio.
Products and Services
Spectrum Pharmaceuticals is at the forefront of innovation in cancer treatment, with a focus on developing products that offer new hope to patients battling cancer. Its pipeline includes:
- Eflapegrastim: A novel, long-acting granulocyte colony-stimulating factor designed to mitigate chemotherapy-induced neutropenia. Unlike traditional short-acting treatments, Eflapegrastim's extended activity aims to provide enhanced protection against infection by stimulating the body's production of white blood cells, thereby improving patients' quality of life during chemotherapy.
- Poziotinib: A cutting-edge irreversible tyrosine kinase inhibitor targeting non-small cell lung cancer (NSCLC) tumors harboring specific mutations. Poziotinib represents a significant advancement in personalized medicine, offering targeted therapy to patients with mutations that make their cancer resistant to other treatments. This focus on molecularly defined cancers underscores Spectrum Pharmaceuticals’ commitment to leading-edge cancer care.
- Anti-CD20-IFNa: An innovative antibody-interferon fusion molecule that marks a new frontier in cancer immunotherapy. Directed against CD20, a protein found on the surface of B cells, this compound is currently in Phase I development for patients with relapsed or refractory non-Hodgkin's lymphoma, including difficult-to-treat diffuse large B-cell lymphoma. The fusion of an antibody with interferon aims to harness the immune system's power more effectively, offering a promising new therapeutic avenue for lymphoma patients.
Contact Information
